| Objective: To observe the effect of huachansu capsule combined with paclitaxel and platinum drugs (TP) regimen on T helper cell (Th)/1Th2 cytokines, vascular growth factor and apoptosis regulatory factors in patients with advanced ovarian cancer. Methods: 102 patients with advanced ovarian cancer who admitted to our hospital from March 2020 to May 2022 were selected, patients were divided into study group (51 cases, huachansu capsule combined with TP regimen chemotherapy) and control group (51 cases, TP regimen chemotherapy ) according to the random number table method. The total clinical effective rate, vascular growth factor, serum Th1/Th2 cytokines, apoptosis regulatory factors and incidence of adverse reactions were compared between two groups. Results: Compared with the total clinical effective rate in control group, the total effective rate in study group was higher (P<0.05). After treatment, the levels of γ-interferon (IFN-γ), interleukin-2 (IL-2) and Bcl-2 related X protein (Bax) in study group were higher than those in control group, and the levels of interleukin-6 (IL-6) and interleukin-4 (IL-4) were lower than those in control group (P<0.05). After treatment, the levels of vascular endothelial growth factor (VEGF), fibroblast growth factor (bFGF), endothelial cell specific molecule-1 (ESM-1), angiopoietin-2 (Ang-2), B cell lymphoma-2 (Bcl-2), survivin and Bcl-2 binding anti-apoptotic gene-1 (Bag-1) in study group were lower than those in control group (P<0.05). There was no significant difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Huachansu capsule combined with TP regimen can prevent the disease progression of patients with advanced ovarian cancer by inhibiting tumor angiogenesis, promoting tumor cell apoptosis and regulating immune function. |
